TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36710105

Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index (PNI) ≤38
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Controlling Nutritional Status (CONUT) score >4
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) ≤91
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Triglycerides, Total Cholesterol, and Body Weight Index (TCBI) ≤1109
Number of subjects: 1371
Study: 36710203

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36710205

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation therapy (ADT)
Number of subjects: 1945

Group type: COMPARATOR
Intervention: Standard criteria and omega score
Number of subjects: 1945
Study: 36710243

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 219
Study: 36710319

Group type: EXPERIMENTAL
Intervention: Direct-To-Home NeuroPsychology (DTH-NP) via phone call and videoconference
Number of subjects: 58

Group type: COMPARATOR
Intervention: Face-to-face neuropsychological assessment
Number of subjects: 58
Study: 36710346

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 434
Study: 36710399

Group type: EXPERIMENTAL
Intervention: roxadustat 2.0 mg/kg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: roxadustat 2.5 mg/kg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: roxadustat
Number of subjects: 92
Study: 36710452

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 0
Study: 36710828

Group type: EXPERIMENTAL
Intervention: Parents of people diagnosed with BPD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Parents of people without a relative with a personality disorder
Number of subjects: 106
Study: 36710894

Group type: EXPERIMENTAL
Intervention: Remote, digitally supported consumer-electronics-based screening
Number of subjects: 100
Study: 36711070

Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC) applied twice daily for 28 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC)
Number of subjects: 41
Study: 36711127

Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) at 3 ms (P3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Evoked potentials (EPs) at 10 ms (P10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of EPs (P3 and P10) and image-derived information
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Image-derived information
Number of subjects: 10
Study: 36711157

Group type: EXPERIMENTAL
Intervention: Deep learning UNet model predicting non-perfused volume (NPV) without MRI contrast agents
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Deep learning UNet model predicting NPV
Number of subjects: 95
Study: 36711188

Group type: EXPERIMENTAL
Intervention: Early Intensive-Upper Limb intervention (EI-UL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Early Intensive-Upper Limb intervention with integrated Multisensory Stimulation And Priming (MuSSAP) training
Number of subjects: 16
Study: 36711615

Group type: EXPERIMENTAL
Intervention: TAG72-CAR T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mbIL12 CAR T cells
Number of subjects: 0
Study: 36711671

Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention (six weekly individual counselling sessions of problem-solving therapy)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention
Number of subjects: 516
Study: 36711869

Group type: EXPERIMENTAL
Intervention: Mifepristone (glucocorticoid receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine (α2 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36711885

Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Written materials (control)
Number of subjects: 222
Study: 36712044

Group type: EXPERIMENTAL
Intervention: Remote monitoring intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 36712105

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (EBI; protocol-based hypertension treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Implementation strategy (team-based collaborative care)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Implementation of the EBI
Number of subjects: 18
Study: 36712398

Group type: EXPERIMENTAL
Intervention: Acoustic-score and CAD-score (cut-off score >20)
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 1464
Study: 36712417

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 0
Study: 36712425

Group type: EXPERIMENTAL
Intervention: Circulating plasma hPG
Number of subjects: 0
Study: 36712451

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF) levels in serum
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF) levels in cerebrospinal fluid (CSF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF) levels in cerebral microdialysate (MD)
Number of subjects: 30
Study: 36712674

Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36712824

Group type: EXPERIMENTAL
Intervention: Pain intensity assessment using patient-reported pain scores on numerical rating scales from 0 to 10
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Surgical debridement and hyperbaric oxygen therapy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pain improvement
Number of subjects: 111
Study: 36712888

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo with triple antiemetic therapy (fosaprepitant, ondansetron, and dexamethasone)
Number of subjects: 349
Study: 36713019

Group type: EXPERIMENTAL
Intervention: Universal Clinician Device (UCD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GARFIELD-AF risk tool (adapted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 36713038

Group type: EXPERIMENTAL
Intervention: Image guidance for LV lead placement
Number of subjects: 30
Study: 36713413

Group type: EXPERIMENTAL
Intervention: AZD1222 vaccine
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 36713499

Group type: EXPERIMENTAL
Intervention: Preoperative hormonal therapy (ADT, ADT+Docetaxel, ADT+Abiraterone)
Number of subjects: 230
Study: 36713567

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus oxaliplatin-based regimens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lipidomics analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cytokine analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple biomarkers model
Number of subjects: 30
Study: 36713601

Group type: EXPERIMENTAL
Intervention: Amazon Alexa voice-assistant screening
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Post-study survey rating of Alexa
Number of subjects: 215
Study: 36713755

Group type: EXPERIMENTAL
Intervention: CTRAN score (predictive model for in-hospital AMI risk)
Number of subjects: 96367
Study: 36713761

Group type: EXPERIMENTAL
Intervention: Rivaroxaban monotherapy
Number of subjects: 2054

Group type: COMPARATOR
Intervention: Rivaroxaban plus antiplatelet therapy (combination therapy)
Number of subjects: 2054
Study: 36713926

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 9
Study: 36714040

Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine administration (group K)
Number of subjects: 127

Group type: COMPARATOR
Intervention: No ketamine administration (group NK)
Number of subjects: 127
Study: 36714101

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 27
Study: 36714197

Group type: EXPERIMENTAL
Intervention: Social app care group (warfarin therapy guided by experienced clinicians via a social app)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Routine care group (warfarin therapy managed through traditional in-office visits)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Social app care group
Number of subjects: 735
Study: 36714602

Group type: EXPERIMENTAL
Intervention: Higher pre-pregnancy BMI
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Women with obesity
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal weight women
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All weight status groups
Number of subjects: 32
Study: 36714639

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol with NIV
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo (nebulized 0.9% NaCl) with NIV
Number of subjects: 608
Study: 36715014

Group type: EXPERIMENTAL
Intervention: hTERT vaccine UV1 combined with androgen deprivation therapy (ADT) and radiotherapy
Number of subjects: 22
Study: 36715152

Group type: EXPERIMENTAL
Intervention: Prasugrel dose de-escalation (5 mg daily)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Conventional therapy (prasugrel 10 mg daily)
Number of subjects: 990
Study: 36715211

Group type: EXPERIMENTAL
Intervention: Porphyromonas gingivalis stimulation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fusobacterium nucleatum stimulation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IL-10-producing B cells in grade C patients
Number of subjects: 81
Study: 36715243

Group type: COMPARATOR
Intervention: Medical/surgical masks
Number of subjects: 610872

Group type: COMPARATOR
Intervention: N95/P2 respirators
Number of subjects: 610872

Group type: COMPARATOR
Intervention: Hand hygiene interventions
Number of subjects: 610872
Study: 36715498

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36715639

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ToxT approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinal log-linear models (OLLM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive analyses and longitudinal modeling approaches
Number of subjects: 0
Study: 36715655

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Fear-avoidance rehabilitation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of antidepressants and fear-avoidance rehabilitation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 36715659

Group type: EXPERIMENTAL
Intervention: POGO <50%
Number of subjects: 104

Group type: COMPARATOR
Intervention: POGO 100%
Number of subjects: 104
Study: 36715712

Group type: EXPERIMENTAL
Intervention: Crush injury
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Neutrophil (NEU) levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Creatine kinase myocardial band (CKMB) levels
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination of crush injury, PT, and NEU
Number of subjects: 221
Study: 36715766

Group type: EXPERIMENTAL
Intervention: Belly dance
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mat Pilates
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 36715850

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily (QD)
Number of subjects: 725
Study: 36716009

Group type: EXPERIMENTAL
Intervention: Vigorous aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36716031

Group type: EXPERIMENTAL
Intervention: SER-109 (4 capsules once daily for 3 days)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 36716092

Group type: EXPERIMENTAL
Intervention: mWACh-PrEP (bidirectional communication platform utilizing two-way SMS text messaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (in-clinic adherence counseling)
Number of subjects: 0
Study: 36716146

Group type: EXPERIMENTAL
Intervention: SkillJoy
Number of subjects: 85

Group type: COMPARATOR
Intervention: ASM
Number of subjects: 85
Study: 36716275

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study: 36716301

Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention (PFI) with cross-tailored dynamic feedback (CDF)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 600
Study: 36716310

Group type: EXPERIMENTAL
Intervention: Evidence-based practices including subglottic suctioning, daily assessment for spontaneous awakening trial (SAT), spontaneous breathing trial (SBT), head of bed elevation, and avoidance of neuromuscular blockers unless otherwise indicated.
Number of subjects: 8523
Study: 36716382

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously plus SoC
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo plus SoC
Number of subjects: 407
Study: 36716407

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 106
Study: 36716415

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 806
Study: 36716451

Group type: EXPERIMENTAL
Intervention: Non-MRI-conditional ICDs
Number of subjects: 629
Study: 36716759

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotics (paliperidone and aripiprazole)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Oral antipsychotics (paliperidone and aripiprazole)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Combined LAI treatment
Number of subjects: 511

Group type: COMPARATOR
Intervention: Combined oral treatment
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Both treatment groups (LAI vs Oral)
Number of subjects: 511
Study: 36716761

Group type: EXPERIMENTAL
Intervention: Emicizumab 3 mg/kg subcutaneously once weekly for 4 weeks, followed by maintenance doses of 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 73
Study: 36716763

Group type: EXPERIMENTAL
Intervention: Prospective audit and feedback plus standard of care
Number of subjects: 886

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 886
Study: 36716780

Group type: EXPERIMENTAL
Intervention: Sex hormones (estrone, estradiol, testosterone, dehydroepiandrosterone)
Number of subjects: 5511

Group type: EXPERIMENTAL
Intervention: SHBG concentrations above quartile 1 (Q1)
Number of subjects: 5511

Group type: EXPERIMENTAL
Intervention: Low SHBG
Number of subjects: 5511

Group type: EXPERIMENTAL
Intervention: Null findings for sex hormones
Number of subjects: 5511
Study: 36716781

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Opiate analgesia (fentanyl)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: No specific intervention (severe pain)
Number of subjects: 336
Study: 36716811

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 106
Study: 36716960

Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions with concurrent i.v. cisplatin (75mg/m2)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Twice-daily thoracic radiotherapy of 60 Gy in 40 fractions with concurrent i.v. cisplatin (75mg/m2)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Time to progression
Number of subjects: 170
Study: 36716991

Group type: EXPERIMENTAL
Intervention: Intensive SBP control (target of 110 to <130 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard SBP control (target of 130 to <150 mmHg)
Number of subjects: 0
Study: 36716989

Group type: EXPERIMENTAL
Intervention: Mentored behavioral and environmental restructuring sleep intervention over four months, including workshops, webinars, text messaging, environmental data, and expert mentoring.
Number of subjects: 0
Study: 36717057

Group type: EXPERIMENTAL
Intervention: Critically ill males and females
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Severely ill females
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Compartmental analysis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study: 36717133

Group type: EXPERIMENTAL
Intervention: Standardised screening process for neurodevelopmental disorders (NDD) using online parental questionnaires (Social Responsiveness Scale, IdentiDys scale, DCDQ, parental concerns) through a web platform.
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Clinical semi-structured interview with a psychologist for siblings with positive screening results.
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Telephone contact with parents approximately 12 months after stage 2.
Number of subjects: 384
Study: 36717134

Group type: EXPERIMENTAL
Intervention: Return home consultation (CREDO management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (conventional management)
Number of subjects: 0
Study: 36717143

Group type: EXPERIMENTAL
Intervention: Preoperative autonomic function monitoring through 20 min of continuous beat-to-beat heart rate and blood pressure monitoring using LiDCO rapid (Masimo Corporation, USA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 180
Study: 36717148

Group type: EXPERIMENTAL
Intervention: Active sTMS treatment for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham sTMS treatment for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: At-home sTMS administration
Number of subjects: 60
Study: 36717150

Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab and nivolumab with SBRT (24 Gray in three fractions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combination of ipilimumab and nivolumab without SBRT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab and nivolumab with SBRT
Number of subjects: 80
Study: 36717163

Group type: EXPERIMENTAL
Intervention: Surgical staging followed by tailored chemoradiation
Number of subjects: 510

Group type: COMPARATOR
Intervention: PET/CT staging followed by chemoradiation (control arm)
Number of subjects: 510
Study: 36717385

Group type: EXPERIMENTAL
Intervention: Daily supplementation with low-dose B vitamins plus betaine (400 μg folic acid, 8 mg vitamin B) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 100
Study: 36717425

Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP) in group 1 (RA + periodontitis)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP) in group 2 (periodontitis patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 80
Study: 36717461

Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation (CTM) applied during non-menstruation days for 2 menstrual cycles (group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation (CTM) applied during non-menstruation days for 3 menstrual cycles (group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study: 36717539

Group type: EXPERIMENTAL
Intervention: Meplazumab 0.12 mg/kg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Meplazumab 0.2 mg/kg
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Meplazumab 0.3 mg/kg
Number of subjects: 167
Study: 36717556

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (Cu-IUD)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Injectable intramuscular depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Levonorgestrel implant (LNG)
Number of subjects: 218
Study: 36717799

Group type: EXPERIMENTAL
Intervention: Telemonitoring (remote web-based eye exams and digital questionnaires)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (regular post-operative consultations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36717833

Group type: EXPERIMENTAL
Intervention: Questionnaire-based classification for migraine and tension-type headaches
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Migraine-tension-type-index
Number of subjects: 253
Study: 36717894

Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1.5 mA cathodal tDCS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 4
Study: 36717911

Group type: EXPERIMENTAL
Intervention: Short sleep duration and circadian misalignment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cognitive function and hedonic eating tendencies
Number of subjects: 120
Study: 36718018

Group type: EXPERIMENTAL
Intervention: Iniparib (5.6 mg/kg IV days 1, 4, 8, and 11) in combination with Carboplatin (AUC 4 IV day 1) and Gemcitabine (1000 mg/m2 IV days 1 and 8)
Number of subjects: 26
Study: 36718142

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg (days 1 and 8) + Cetuximab 250 mg/m2
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Avelumab + Cetuximab + Chemotherapy
Number of subjects: 43